Lately, a phase I clinical trial (NCT01722149) enrolled four patients with metastatic pleural mesothelioma (MPM) using FAP targeting CAR T-cells (CART-FAP) have been reported safe, with major SAEs including upper respiratory infection and thromboembolic event. Here, FAP is linked to respiratory tract infectious disorder.